4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and
development company, today announced the start of dosing in a
First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a
novel multi-target kinase inhibitor, with particular specificity against
selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3
mutants and vascular endothelial growth factor receptors (VEGF-R).
This randomised, double-blind, placebo-controlled, dose-escalation study
investigates the safety, tolerability, pharmacokinetics and
pharmacodynamics of 4SC-203, administered as single dose intravenously,
in 50 volunteers and comprises seven treatment cohorts. In the first
cohort, an initial low dose of 4SC-203 has been applied for safety
observations. Subsequent dose escalating cohorts will include eight
volunteers each randomised at a 4SC-203 to placebo ratio of 6:2. The
trial is expected to last for approximately six months and to report
results in 2010.